• PP 2 (AG 1879): Reading Src Signals in ROS Assays

  2026-08-22

  PP 2 (AG 1879) is a selective Src-family kinase probe for cancer research, immune signaling, and pathway dissection. This article explains how a vascular ROS study changes PP 2 assay design, concentration selection, and interpretation of causality.

• Substance P: From NK-1 Biology to Assay Design

  2026-08-22

  Substance P is a tachykinin neuropeptide central to pain transmission research, neuroimmune signaling, and inflammation studies. This guide connects NK-1 receptor biology with practical peptide handling and explains how spectral-interference research can improve assay quality without replacing functional validation.

• Macrophage EV miR-660 Drives Breast Cancer Metastasis

  2026-08-21

  The reference study defines a macrophage-to-tumor communication pathway in which extracellular vesicles transfer miR-660 into breast cancer cells, suppressing KLHL21 and activating the IKKβ/NF-κB p65 axis. By combining tissue analyses, mechanistic cell experiments, extracellular-vesicle co-culture, and mouse metastasis models, it provides a coherent framework for understanding how tumor-associated macrophages promote breast cancer invasion.

• Bile Acid Retention and Immune Escape in MASH-HCC

  2026-08-20

  A 2026 Cancer Letters study identifies a GPR120–FXR/ABCB11–bile acid–NLRC5 pathway that links lipid-associated metabolic dysfunction to defective MHC-I antigen presentation in MASH-HCC. Its findings suggest that reducing intracellular bile acid retention can restore tumor antigenicity and improve anti-PD-1 responses, while also providing a framework for mechanistic antigen-presentation assays.

• Rapamycin as an mTOR Probe in Neuroinflammation

  2026-08-20

  Rapamycin (Sirolimus) is more than a canonical mTOR inhibitor: it can serve as a pathway-level comparator for separating inflammatory and synaptic mechanisms in experimental depression models. This article connects compartment-resolved immune phenotyping with practical assay design, controls, and translational limitations.

• PCI-32765 (Ibrutinib) BTK Research Workflows

  2026-08-19

  Build reproducible PCI-32765 assays for B-cell receptor signaling inhibition, chronic lymphocytic leukemia research, and exploratory genotype-aware studies. This guide combines formulation, dose-response design, covalent-target validation, and troubleshooting while clearly separating established BTK applications from ATRX-deficient glioma hypotheses.

• XAV939, Wnt/β-Catenin, and DSS Colitis

  2026-08-19

  A 2025 study found that XAV939 successfully inhibited Wnt/β-catenin signaling and reduced SOX9 expression in DSS-induced ulcerative colitis, but did not improve intestinal morphology or inflammatory status. The findings challenge the assumption that pathway suppression alone is sufficient to restore epithelial differentiation or relieve colitis.

• 2'3'-cGAMP: STING Assay Workflows

  2026-08-18

  Use 2'3'-cGAMP (sodium salt) as a defined STING agonist to separate cGAS activation from downstream TBK1–IRF3 signaling. This workflow-focused guide covers formulation, pathway validation, inhibitor profiling, and troubleshooting for innate immunity and immunotherapy research.

• CAMLs in Blood: Phenotyping and Clinical Utility

  2026-08-18

  The reference study reframes circulating cancer-associated macrophage-like cells as biologically active, polyploid giant cells rather than incidental inflammatory debris. Across a prospective, multi-institutional cohort, these cells correlated with progression and disease spread while displaying self-renewal, proangiogenic, and mixed myeloid, epithelial, and endothelial features.

• Merimepodib (VX-497): IMPDH Research Workflows

  2026-08-17

  Merimepodib (VX-497) gives researchers a selective way to test how guanine nucleotide depletion affects lymphocyte proliferation, viral replication, and broader disease models. This workflow-focused guide covers dose design, guanosine rescue, PEDV assays, formulation controls, and troubleshooting for reproducible IMPDH research.

• RIPA Lysis Buffer Strong: Assay-Design Guide

  2026-08-17

  RIPA Lysis Buffer Strong combines powerful membrane solubilization with flexible inhibitor customization. This assay-design guide connects its chemistry to Western blotting, immunoprecipitation, ELISA, kinase workflows, and mechanistic insights from uPAR–uPA cancer research.

• NBC19 NLRP3 Inflammasome Inhibitor Workflow

  2026-08-16

  NBC19 provides a practical way to separate NLRP3-dependent IL-1β release from upstream priming and downstream inflammatory effects. This workflow combines differentiated THP1 assays with a carefully bounded extension into lactate-HMGB1 and sepsis research, emphasizing controls, fresh compound handling, and stimulus-specific optimization.

• Multiple Myeloma Cell Lines: Mutations and Drug Resistance

  2026-08-15

  This Theranostics study built a broad exome-based view of genetic variation across human multiple myeloma cell lines and connected recurrent alterations with signaling pathways and drug response. Its main practical contribution is a framework for selecting molecularly appropriate models for hematological malignancy research rather than relying on a small, poorly characterized set of cell lines.

• β-Elemene C5505: Reliable Cell Assay Workflows

  2026-08-14

  This scenario-driven guide explains how β-Elemene (SKU C5505) can improve reproducibility in viability, adipogenesis, apoptosis, and pathway-focused assays. It combines product-specific handling data with findings from a 3T3-L1 study to support better concentration selection, solvent control, interpretation, and vendor evaluation.

• MK-571: A Dual-Pathway Assay Strategy

  2026-08-14

  MK-571 (L-660,711) is more than a leukotriene D4 receptor antagonist: its ABCC1/MRP1 activity can materially shape macrophage chemotherapy assays. This guide explains how to separate receptor pharmacology from transporter-dependent redox protection in inflammation and drug-resistance research.

8300 records 1/554 page Next 12345 下5页 Last page